MentalHealthDaily

ADHD Genetics Linked to Autism & Schizophrenia But Not Other Psychiatric Conditions (2024 Study)

by GLOOM

Attention Deficit Hyperactivity Disorder (ADHD) is a complex neurodevelopmental condition that significantly impacts individuals’ lives. Recent advancements in genetic research, particularly Mendelian Randomization (MR) studies, have begun to unravel the intricate genetic associations between ADHD and other psychiatric disorders, offering new insights into their comorbidities. By leveraging data from genome-wide association studies (GWAS), this research …

Cannabis (Marijuana) Use & Psychosis: Does It Increase Risk? (2023 Evidence Review)

by GLOOM

The relationship between cannabis (marijuana) use and psychosis has been a topic of considerable scientific interest and public health concern. With changing legal statuses and societal attitudes towards cannabis use in many countries, understanding this relationship is more critical than ever. Highlights: Systematic reviews and meta-analyses show a consistent association between cannabis use and increased …

Genetic Risk for Low Vitamin D Linked to Lower Social Motivation in First-Episode Psychosis (2024 Study)

by GLOOM

Recent research reveals a notable association between vitamin D levels and the severity of negative symptoms in individuals with first-episode psychosis (FEP). A new study explored the genetic predisposition towards lower vitamin D levels and its impact on symptom severity in schizophrenia and related disorders. Highlights: Vitamin D & Psychosis Connection: Lower levels of vitamin …

MicroRNA Biomarkers May Help Diagnose Schizophrenia

by GLOOM

Schizophrenia (SZ) is a complex psychiatric disorder characterized by a myriad of symptoms, typically divided into positive, negative, and cognitive categories. Despite the prevalence and severity of this condition, current diagnostic methods are largely based on subjective clinical interviews and observations, leading to potential misdiagnosis and delayed treatment. Recent studies have focused on microRNAs (miRNAs) …

Vraylar (Cariprazine) & Weight Gain vs. Loss: What You Should Know

by GLOOM

Vraylar (Cariprazine), also sold under the name Reagila [in European countries], is an atypical antipsychotic developed by the pharmaceutical company Allergan. In 2015, Vraylar received FDA approval for the treatment of schizophrenia and mania associated with bipolar disorder. From a pharmacodynamic perspective, Vraylar functions predominantly as a partial agonist at D3 and D2 dopamine receptors, …

Vraylar (Cariprazine) Approved For Schizophrenia & Bipolar Disorder

by GLOOM

Vraylar (Cariprazine) was approved by the FDA on September 17, 2015 for the treatment of schizophrenia and mania associated with bipolar disorder. In clinical trials, the drug was referenced as “RGH-188” – containing Cariprazine as the primary active ingredient. The drug had completed Phase III clinical trials in 2012, and was pending FDA approval for …

20+ New Schizophrenia Medications In Development (2015)

by GLOOM

It is estimated that over 2.5 million adults in the United States have been diagnosed with schizophrenia; this equates to approximately 1.1% of the population. There are many different types of schizophrenia, in fact, genetic clusters suggest it is 8 distinct diseases. Therefore not everyone diagnosed with schizophrenia has the same set of symptoms. Certain …